{
      "Rank": 310,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Application of IMP on patients wound",
            "Application of IMP on patients wound",
            "Application of IMP on patients wound",
            "Application of IMP on patients wound"
      ],
      "ArmGroupInterventionName": [
            "Biological: allo-APZ2-CVU",
            "Drug: Placebo",
            "Biological: allo-APZ2-CVU",
            "Biological: allo-APZ2-CVU"
      ],
      "ArmGroupLabel": [
            "allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm\u00b2)",
            "Placebo",
            "allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm\u00b2)",
            "allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm\u00b2)"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator",
            "Experimental",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04971161"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of CVUs) and safety (by monitoring adverse events [AEs]) of three dose groups of the investigational medicinal product (IMP) allo-APZ2-CVU, topically administered on target wounds of patients with CVU compared to placebo."
      ],
      "BriefTitle": [
            "Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)"
      ],
      "CentralContactEMail": [
            "office@rheacell.com",
            "anna.moessmer@rheacell.com"
      ],
      "CentralContactName": [
            "Christoph Ganss, Dr.",
            "Anna M\u00f6\u00dfmer"
      ],
      "CentralContactPhone": [
            "+49 6221 71833",
            "+49 6221 71833"
      ],
      "CentralContactPhoneExt": [
            "0",
            "0"
      ],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "INDUSTRY",
            "INDUSTRY"
      ],
      "CollaboratorName": [
            "FGK Clinical Research GmbH",
            "Ticeba GmbH"
      ],
      "CompletionDate": [
            "August 2023"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Skin Ulcer Venous Stasis Chronic"
      ],
      "ConditionAncestorId": [
            "D000010335",
            "D000014648",
            "D000014652",
            "D000002318",
            "D000007871",
            "D000012871"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes",
            "Varicose Veins",
            "Vascular Diseases",
            "Cardiovascular Diseases",
            "Leg Ulcer",
            "Skin Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC26",
            "All",
            "BC14",
            "BC17",
            "BC23",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Wounds and Injuries",
            "All Conditions",
            "Heart and Blood Diseases",
            "Skin and Connective Tissue Diseases",
            "Symptoms and General Pathology",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Venous Stasis",
            "Ulcer",
            "Skin Ulcer"
      ],
      "ConditionBrowseLeafId": [
            "M16837",
            "M16547",
            "M16358",
            "M14838",
            "M16548",
            "M16552",
            "M10035",
            "M14826",
            "T1303"
      ],
      "ConditionBrowseLeafName": [
            "Wounds and Injuries",
            "Varicose Ulcer",
            "Ulcer",
            "Skin Ulcer",
            "Varicose Veins",
            "Vascular Diseases",
            "Leg Ulcer",
            "Skin Diseases",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "low",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000014647",
            "D000012883",
            "D000014456"
      ],
      "ConditionMeshTerm": [
            "Varicose Ulcer",
            "Skin Ulcer",
            "Ulcer"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [
            "Randomized, placebo-controlled, double-blind, dose-ranging, interventional, multicenter, phase IIb clinical trial"
      ],
      "DesignMasking": [
            "Double"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Investigator"
      ],
      "DetailedDescription": [
            "This is a randomized, placebo-controlled, double-blind, dose-ranging, multicenter, phase IIb clinical trial to investigate the efficacy and safety of the IMP allo-APZ2-CVU on wound healing in patients with therapy-resistant CVU. The allogeneic IMP allo-APZ2-CVU contains skin-derived ABCB5-positive dermal mesenchymal stromal cells isolated from skin tissue of healthy donors and stored in a donor cell bank.\n\nPatients will be randomized to be treated with allo-APZ2-CVU (dose 1, dose 2, dose 3) or placebo (50 patients per dose group). The patients will undergo treatment with the IMP on Day 0 (V3) and will be followed up for efficacy for 18 weeks (V4 until V14). Two safety follow-up visits will be performed at Month 6 (V15) and Month 10 (V16).\n\nThe wound healing process will be documented by standardized photography. The wound size measurement will start at the first Screening Visit (V1) and will be measured at each following on-site visit.\n\nPain will be assessed using a numerical rating scale and quality of life will be investigated with standardized and validated questionnaires."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMale or female patients at least 18 years old;\nChronic venous leg ulcer (as defined by the current AWMF guidelines: therapy-resistant ulcer that shows no tendency to heal within 3 months despite of optimal phlebological therapies or has not fully healed within 12 months) at lower leg and/or ankle region and has not been present longer than 15 years, diagnosed by doppler or duplex sonography, ankle brachial index (ABI, 0.9-1.3), physical examination and dermatological review;\nWound size of target ulcer between 1 and 50 cm\u00b2 measured by a standardized photography at the screening visits (Visit 1 and Visit 2);\nIf patients have 2 or more ulcers at the same extremity, the target ulcer has to be separated by a minimum bridge of 1 cm of epithelialized skin from other ulcers (the largest ulcer should be the target ulcer, if not decided otherwise at discretion of the investigator; the target ulcer is defined at Visit 1);\nBody mass index between 15 and 50 kg/m\u00b2;\nPatients understand the nature of the procedure and are providing written informed consent prior to any clinical trial procedure;\nWomen of childbearing potential must have a negative blood pregnancy test at Visit 1;\nWomen of childbearing potential and their partner must be willing to use highly effective contraceptive methods during the course of the clinical trial.\n\nExclusion Criteria:\n\nEvidence of the ulcer extending to the underlying muscle, tendon, or bone;\nDiabetes mellitus that has to be confirmed by blood test (Hemoglobin A1c >7.5%);\nPeripheral Artery Disease including claudication with need of treatment;\nAcute deep vein thrombosis (maximum 30 days from diagnosis) or a still untreated deep vein thrombosis;\nUnable to tolerate leg ulcer compression bandage;\nInfection of the target ulcer requiring treatment as judged clinically;\nAll diagnosed disorders, unrelated to CVU, that are influencing wound healing of the target wound at investigator's discretion;\nCurrent use of medications that influence wound healing: systemic immunosuppressives, cytotoxic medicinal products, and systemic steroids (above Cushing-threshold level);\nPatient who, in the opinion of the investigator, for any reason are unable or unwilling to complete the trial per protocol (e.g. alcohol or substance abuse, not mobile, short life expectancy) or there is evidence of any other medical condition (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment;\nAny malignancy within the past 5 years, excluding successfully treated carcinoma in situ, basal cell carcinoma or squamous cell carcinoma of the skin without evidence of metastases;\nPregnant or lactating women;\nAny known allergies to components of the IMP;\nPrior surgical procedures such as bypass or mesh-graft treatment at target leg within 2 months prior to Visit 1 at target leg;\nPatients with significant ulcer healing or wound size enlargement of more than 25% at Visit 2 compared to Visit 1;\nTreatment of target ulcer with active wound care agents (e.g. Iruxol\u00aeN), which have not been paused 14 days before IMP application;\nCurrent or previous (within 30 days of enrollment) treatment with another IMP, or participation and/or under follow-up in another clinical trial;\nPrevious participation in this clinical trial (except for screening failures due to an inclusion or exclusion criterion);\nEmployees of the sponsor, or employees or relatives of the investigator."
      ],
      "EnrollmentCount": [
            "200"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm\u00b2)",
            "allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm\u00b2)",
            "allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm\u00b2)",
            "Placebo"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Suspension of ABCB5-positive dermal mesenchymal stromal cells. One topical application with a syringe.",
            "One topical application with a syringe"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "allo-APZ2-CVU",
            "Placebo"
      ],
      "InterventionOtherName": [
            "Skin-derived ABCB5-positive dermal mesenchymal stromal cells"
      ],
      "InterventionType": [
            "Biological",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Chronic Venous Ulcer",
            "ABCB5",
            "Allogeneic",
            "Dermal mesenchymal stromal cells",
            "varicose ulcer",
            "skin ulcer",
            "advanced therapy medicinal product",
            "somatic cell therapy",
            "phase IIb"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "September 21, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "September 20, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "RHEACELL GmbH & Co. KG"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Augsburg",
            "Bad Bentheim",
            "Berlin",
            "Berlin",
            "Berlin",
            "Bochum",
            "Bochum",
            "Braunschweig",
            "Bremerhaven",
            "Dresden",
            "Dresden",
            "D\u00fcsseldorf",
            "Erlangen",
            "Essen",
            "Freiburg",
            "Gelsenkirchen",
            "Gera",
            "Halle",
            "Hamburg",
            "Hanau",
            "Karlsbad",
            "Kiel",
            "Krefeld",
            "Langenau",
            "Leipzig",
            "Leipzig",
            "Ludwigshafen",
            "Memmingen",
            "M\u00fcnchen",
            "M\u00fcnchen",
            "M\u00fcnster",
            "N\u00fcrnberg",
            "Potsdam",
            "Regensburg",
            "Rostock",
            "Schwerin",
            "Stuttgart",
            "T\u00fcbingen",
            "Wuppertal",
            "W\u00fcrzburg"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [
            "Julia Welzel, Prof. Dr.",
            "Athanasios Tsianakas, PD Dr. med.",
            "Berthold Amann, Dr. med.",
            "Oliver C. Thamm, PD Dr. med.",
            "Daniel Schiltz, Dr. med.",
            "Johannes Niesmann, Dr. med.",
            "Markus St\u00fccker, Prof. Dr.",
            "Herms Wittstock, Dr. med.",
            "Michael M. Sachse, Dr. med.",
            "Peter Heymer, Dr. med.",
            "Cornelia Erfurt-Berge, PD Dr. med.",
            "Joachim Dissemond, Prof. Dr.",
            "Dimitra Kiritsi, PD Dr. med.",
            "Mansur Duran, PD Dr. med.",
            "Sabine Sell",
            "Abdou Zarzour, Dr. med.",
            "Matthias Augustin, Prof. Dr.",
            "Hans Michael Ockenfels, Prof. Dr.",
            "R\u00fcdiger von Bauer, Dr. med.",
            "Harald Br\u00fcning, Dr. med.",
            "Beate Schwarz, Dr. med.",
            "Jan C. Simon, Prof. Dr.",
            "Christian Schubert, Dr. med.",
            "Lutz Stemler, Dr. med.",
            "Andreas Schwinn, Dr. med.",
            "Daniela Hartmann, PD Dr. med.",
            "Tobias G\u00f6rge, Prof. Dr.",
            "Erwin S. Schultz, Prof. Dr.",
            "Khusru Asadullah, Prof. Dr.",
            "Stephan Seitz, PD Dr. med.",
            "Susen Rode",
            "Frank Masberg, Dr. med.",
            "Nicolas Leitz, Dr. med.",
            "Anke Str\u00f6lin, Prof. Dr.",
            "Silke C. Hofmann, Prof. Dr.",
            "Andreas Kerstan, PD Dr. med."
      ],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact"
      ],
      "LocationCountry": [
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany",
            "Germany"
      ],
      "LocationFacility": [
            "Universit\u00e4tsklinikum Augsburg, Klinik f\u00fcr Dermatologie und Allergologie, Campus S\u00fcd",
            "Fachklinik Bad Bentheim, Dermatologische Ambulanz",
            "Franziskus-Krankenhaus Berlin, Klinik f\u00fcr Innere Medizin, Angiologie und Diabetologie",
            "Helios Klinikum Berlin-Buch, Klinik f\u00fcr Plastische und \u00c4sthetische Chirurgie",
            "Helios Klinikum Emil von Behring, Klinik f\u00fcr Plastische und \u00c4sthetische Chirurgie",
            "Hautarztpraxis Dr. Niesmann & Dr. Othlinghaus, Hautzentrum im Jahrhunderthaus",
            "Katholisches Klinikum Bochum gGmbH, Venenzentrum der Kliniken f\u00fcr Dermatologie und Gef\u00e4\u00dfchirurgie der Ruhr-Universit\u00e4t Bochum",
            "Haut\u00e4rzte Braunschweig am Altstadtmarkt, Haut\u00e4rztliche Gemeinschaftspraxis",
            "Klinikum Bremerhaven Reinkenheide gGmbH, Klinik f\u00fcr Dermatologie, Allergologie und Phlebologie, Wundzentrum",
            "Klinische Forschung Dresden GmbH",
            "Universit\u00e4tsklinikum \"Carl Gustav Carus\" der Technischen Universit\u00e4t Dresden, Medizinische Klinik und Poliklinik III Angiologie und Gef\u00e4\u00dfzentrum",
            "Universit\u00e4tsklinikum D\u00fcsseldorf, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, Klinik f\u00fcr Dermatologie",
            "Universit\u00e4tsklinikum Erlangen, Hautklinik - Wundzentrum Dermatologie",
            "Universit\u00e4tsklinikum Essen, Klinik und Poliklinik f\u00fcr Dermatologie, Venerologie und Allergologie",
            "Universit\u00e4tsklinikum Freiburg, Klinik f\u00fcr Dermatologie und Venerologie",
            "Marienhospital Gelsenkirchen GmbH, Klinik f\u00fcr Chirurgie (Allgemein-, Viszeral- und Endokrine Chirurgie, Thorax-, Gef\u00e4\u00df- und Endovaskul\u00e4re Chirurgie und Kinderchirurgie)",
            "SRH Wald-Klinikum Gera GmbH, Zentrum f\u00fcr Klinische Studien",
            "Praxis Dr. med. Abdou Zarzour",
            "Universit\u00e4tsklinikum Hamburg- Eppendorf, Institut f\u00fcr Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP)",
            "MVZ Prof. Dr. Ockenfels, Haut und Allergie-Praxisklinik GmbH",
            "SRH Klinikum Karlsbad- Langensteinbach GmbH, Interdisziplin\u00e4res Gef\u00e4\u00dfzentrum Innere Medizin",
            "Medizinisches Versorgungszentrum DermaKiel GmbH",
            "Helios Klinikum Krefeld, Klinik f\u00fcr Dermatologie und Venerologie",
            "Hautarztpraxis Langenau, Studienzentrum",
            "Universit\u00e4tsklinikum Leipzig A\u00f6R, Klinik und Poliklinik f\u00fcr Dermatologie, Venerologie und Allergologie",
            "Studienambulanz Dr. Schubert Leipzig",
            "Diabetologikum Ludwigshafen, die Praxis am Ludwigsplatz",
            "Beldio Research GmbH",
            "Klinikum der Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Klinik und Poliklinik f\u00fcr Dermatologie und Allergologie",
            "Dermazentrum M\u00fcnchen, Standort Neuhausen, Studienzentrum",
            "Universit\u00e4tsklinikum M\u00fcnster, Klinik f\u00fcr Hautkrankheiten, Allgemeine Dermatologie und Venerologie",
            "Klinikum N\u00fcrnberg Nord, Klinik f\u00fcr Dermatologie",
            "Hautarztpraxis Prof. Dr. med. Khusru Asadullah",
            "Caritas-Krankenhaus St. Josef, Klinik f\u00fcr Plastische und \u00c4sthetische, Hand- und Wiederherstellungschirurgie",
            "Universit\u00e4tsmedizin Rostock, Klinik und Poliklinik f\u00fcr Dermatologie und Venerologie",
            "Helios Kliniken Schwerin, Plastische, Rekonstruktive und \u00c4sthetische Chirurgie",
            "Haut\u00e4rztliche Gemeinschaftspraxis Dr. Leitz und Kollegen",
            "Universit\u00e4tsklinikum T\u00fcbingen, Universit\u00e4ts-Hautklinik T\u00fcbingen",
            "Helios Universit\u00e4tsklinikum Wuppertal, Zentrums f\u00fcr Dermatologie, Allergologie und Dermatochirurgie",
            "Universit\u00e4tsklinikum W\u00fcrzburg, Klinik und Poliklinik f\u00fcr Dermatologie, Venerologie und Allergologie"
      ],
      "LocationState": [],
      "LocationStatus": [
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Not yet recruiting",
            "Not yet recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Withdrawn",
            "Withdrawn",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Withdrawn",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Withdrawn",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting"
      ],
      "LocationZip": [
            "86179",
            "48455",
            "10787",
            "13125",
            "14165",
            "44793",
            "44805",
            "38100",
            "27574",
            "01069",
            "01307",
            "40225",
            "91054",
            "45147",
            "79104",
            "45886",
            "07548",
            "06108",
            "20246",
            "63450",
            "76307",
            "24148",
            "47805",
            "89129",
            "04103",
            "04315",
            "67059",
            "87700",
            "80337",
            "80636",
            "48149",
            "90419",
            "14467",
            "93053",
            "18057",
            "19049",
            "70178",
            "72076",
            "42283",
            "97080"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Randomized, Placebo-Controlled, Double-blind, Dose-Ranging, Multicenter, Phase IIb Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Chronic Venous Ulcer (CVU)"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "RHEACELL GmbH & Co. KG"
      ],
      "OrgStudyId": [
            "allo-APZ2-CVU-IIb"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Klinik und Poliklinik f\u00fcr Dermatologie, Venerologie und Allergologie, W\u00fcrzburg"
      ],
      "OverallOfficialName": [
            "Andreas Kerstan, Dr."
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "August 2023"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Complete wound closure at Week 18 already persisting for at least two weeks will be evaluated.",
            "All AEs occurring during the clinical trial will be registered, documented and evaluated."
      ],
      "PrimaryOutcomeMeasure": [
            "Complete wound closure at Week 18 already persisting for at least two weeks",
            "Assessment of adverse event (AE) occurrence"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Week 18",
            "Up to 10 months"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Wound size change in percent at each post-baseline follow-up visit will be evaluated.",
            "Time to complete wound closure will be evaluated.",
            "Complete wound closures at each post-baseline follow-up visit will be evaluated.",
            "Duration of wound closure will be evaluated.",
            "Recurrence of the wound will be evaluated.",
            "The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the amount and type of wound exudate.",
            "The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the formation of granulation tissue together with epithelialization.",
            "The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the questions regarding scar formation.",
            "Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14 will be evaluated.",
            "Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit will be evaluated.",
            "A physical body examination (e.g. general appearance, thyroid, head, lungs and thorax, ears, cardiovascular system, eyes, abdomen, nose-mouth-throat, musculoskeletal system, skin, extremities, lymph nodes, neurological system) will be performed and abnormal physical examination results will be evaluated and reported as AEs."
      ],
      "SecondaryOutcomeMeasure": [
            "Wound size change in percent at each post-baseline follow-up visit",
            "Time to complete wound closure",
            "Complete wound closures at each post-baseline follow-up visit",
            "Duration of wound closure",
            "Recurrence of the wound",
            "Quality of wound healing (wound exudate) at each post-baseline follow-up visit",
            "Quality of wound healing (granulation tissue together with epithelialization) at each post-baseline follow-up visit",
            "Quality of wound healing (scar formation) at each post-baseline follow-up visit",
            "Assessment of Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14",
            "Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit",
            "Physical examination and vital signs at V14"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
            "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
            "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
            "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
            "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
            "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
            "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
            "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
            "Week 6, 12, 18",
            "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
            "Week 18"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "August 18, 2021"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "September 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "July 21, 2021"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "June 7, 2021"
      ],
      "StudyFirstSubmitQCDate": [
            "July 12, 2021"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}